Tag

Tagged: medical adoption

Sponsored
1 day, 16 hours ago

Innovation Isn’t Broken - Translation Is

HealthPad
Directory:
Medical Technology
Tags:
commentary
medical adoption
medical innovation
medical invention
MedTech
technical talent

  • Healthcare’s biggest bottleneck isn’t invention - it’s adoption
  • Breakthroughs fail not in the lab, but in real-world delivery
  • Translation, not technology, now determines impact and scale
  • Pilots, proof-points, and performance metrics are not progress
  • The next winners in healthcare will master translation, not disruption

Innovation Isn’t Broken - Translation Is

Healthcare likes to describe itself as an innovation problem. It is more accurately a translation problem.

There is no obvious shortage of science, capital or technical ambition. The sector continues to produce novel therapeutics, increasingly sophisticated diagnostics and a steady flow of digital tools, AI systems and platform technologies. The research base is deep, venture funding remains substantial, and the intellectual energy is hard to miss. On the supply side, innovation is not the constraint.

The constraint is adoption.

Most new ideas are generated at the edge of the system: universities, research institutes and venture-backed companies set up to explore uncertainty, move quickly and tolerate failure. Large healthcare organisations are designed to do almost the opposite. Their job is to deliver safe, regulated, continuous services at scale. Their incentives favour reliability, budget control and operational stability. That is not a cultural bug. It is the operating model.

For investors and senior decision-makers, this distinction is crucial. The question is often not whether a technology is promising, but whether an institution can absorb it without friction becoming fatal. The benefits of early adoption are typically strategic, long-term and hard to attribute. The costs are immediate and personal: disrupted workflows, procurement complexity, governance burden, implementation risk and reputational exposure. Faced with that asymmetry, incumbents behave rationally. They wait.

The result is familiar: a sector rich in invention but weak in diffusion. Technologies clear technical hurdles, complete pilots and sometimes secure regulatory approval, yet still fail to reach routine use at meaningful scale. Value leaks in the gap between proof and practice.

That gap deserves more attention than it gets. It is where returns are delayed, partnerships stall and otherwise credible innovation underperforms commercially. The next advantage in healthcare will not come from inventing more. It will come from reducing the institutional friction between what the science makes possible and what the system can deploy.

Innovation is abundant. Translation is scarce. Scarce capabilities tend to matter most.
India is rewriting the healthcare playbook. Fortress hospitals are giving way to asset-light care models centred on specialised clinics, distributed networks, and scalable, high-volume delivery. For Western MedTechs eyeing India, the signal is clear: success will depend less on hospital bed expansion than on modular technologies, flexible pricing, and products built for decentralised care. Those who crack this model will not just win in India - they will help shape the future blueprint of global healthcare. 
 
In this Commentary

Healthcare is not short of ideas - it is short of impact. This Commentary argues that the barrier to progress is not innovation, but translation: the work of turning breakthroughs into routine care. From digital health and MedTech to life sciences and AI, it explores why promising innovations stall, and why the next winners in healthcare will be those who design, lead, and invest for adoption, not just invention.
 
The myth of the innovation deficit

Across healthcare, life sciences and MedTech, innovation is not scarce. It is abundant. Capital, technical talent and scientific output remain substantial. Therapeutics move faster, diagnostics are more capable, and AI continues to expand the range of clinically relevant tasks it can support.

If invention were the constraint, the sector would look different. Outcomes, workflows and productivity would be improving more consistently. Instead, progress remains uneven. Promising technologies clear technical and regulatory hurdles, attract attention and complete pilots, yet still fail to reach routine use at scale.

That points to a different problem. Healthcare does not struggle to generate new ideas. It struggles to absorb them.

For investors, executives and directors, that distinction matters. Translation does not begin at launch. It begins when incumbent organisations decide that engaging external innovation is a strategic priority, and commit time, capability and leadership attention accordingly. Without that, technologies remain interesting but peripheral.

The shortage in healthcare is not innovation. It is the institutional capacity to turn innovation into operational reality.
 
Translation is where innovation becomes real

In healthcare, innovation is often mistaken for invention. For investors, executives and directors, that is the wrong emphasis. An idea does not create value when it is published, funded or approved. It creates value when it is adopted, trusted and embedded in routine use. Translation is the process that closes that gap.

That process is more onerous than many outside the sector assume. It runs through regulation, reimbursement, procurement, workflow redesign, training, professional buy-in and operational support. At each stage, the number of stakeholders increases, incentives diverge and institutional resistance hardens. Most innovations do not fail because the science is weak. They fail because the path to adoption is too brittle.

This is where many healthcare incumbents are exposed. Large organisations know how to manage incremental change: software upgrades, compliance projects, pathway refinements and controlled efficiency programmes. Fewer retain the internal capability required for step-change adoption, where evidence is still developing, workflows must be reworked and implementation depends on learning in real time.
You might also like to listen to:
 
Over time, the functions that once bridged research and delivery have been diluted, outsourced or split across silos with no clear ownership. Translation becomes everybody’s concern and nobody’s mandate. The result is governance without execution: institutions capable of slowing decisions, but less capable of making new technologies stick.

That matters commercially. The constraint on returns is often not invention, but absorption. Healthcare does not lack breakthroughs. It lacks the operational discipline to convert promising technologies into repeatable outcomes at scale. Translation, not novelty, is where value is realised.
A system designed to resist frictionless adoption
 
Healthcare is not a consumer market and attempts to treat it as one usually end badly. Adoption is not driven primarily by branding, user growth or clever distribution. It is shaped by regulation, liability, clinical accountability and the fact that mistakes carry serious consequences. Caution is not evidence of a broken market. It is one of the ways the system protects patients.

That has important implications for capital allocation and strategy. Clinicians do not adopt products because they are novel; they adopt them when they are safe, trusted and compatible with clinical responsibility. Organisations do not buy because a technology is exciting; they buy when it fits budgets, workflows and risk thresholds. The issue is not persuasion. It is alignment.

This is where many otherwise credible technologies come unstuck. They are built on an assumption that healthcare adoption is linear: prove efficacy, secure approval, then scale. In practice, the system is slow-moving, capacity-constrained and full of institutional trade-offs. Anything that requires new workflows, new governance or new behaviour competes with immediate operational pressures.

The result is rarely outright rejection. More often, it is drift: interest without ownership, evaluation without integration, and activity without adoption.
 
Designing for translation, not just performance

A recurring weakness in healthcare innovation is technical strength without operational fit. Products perform in controlled settings, then struggle in live environments where time is limited, workflows are fragile and trade-offs are constant. Data are produced without a clear route to action. Tools promise efficiency while adding burden.

The structural problem is well known. Innovation is generated at the edge - in start-ups and research centres - while decision rights, budgets and operational control sit with incumbents. The incentives differ accordingly: innovators are rewarded for speed and novelty; large organisations for continuity, compliance and risk control. Without active leadership to bridge that divide, promising technologies remain distant from the conditions required for adoption.

For investors, executives and directors, the question is not whether something works, but whether it will be used. Which decision does it improve? Where does it sit in the workflow? Who pays, who benefits and who carries the risk?

These are not procurement questions to be left until later. They are design inputs. Products built around trust, accountability and operational fit are more likely to move beyond pilots and into routine use at scale.
 
Digital health’s cautionary tale
 
The translation gap is easiest to see in digital health. Over the past decade, the sector produced no shortage of platforms, apps and workflow tools promising to improve care. Many were well designed, clinically credible and positively received in pilots. Capital was plentiful, case studies followed, and expectations rose accordingly.

Yet relatively few achieved durable adoption at scale.

The problem was not a lack of innovation. It was a failure of integration. Too many products sat outside the clinical core, asking already stretched staff to adopt another interface, another workflow and another stream of data. Some improved patient engagement while adding to clinician burden. Others addressed abstract inefficiencies rather than the operational realities of care delivery. The technology often worked. The system around it did not.

Leadership has also been part of the story. Many senior teams understand risk, compliance and service continuity better than software iteration or product-led change. That is an institutional fact, not a personal failing. But it means the burden of adoption is often pushed onto IT teams and frontline champions.

Digital health does not fail because it is digital. It fails when translation is treated as an afterthought.
 
MedTech beyond the device

MedTech is at an inflection point. Technical innovation remains strong, but the source of value has shifted. Hardware alone is no longer enough. Success is increasingly determined by the surrounding ecosystem - software, data, services, evidence generation, and integration into clinical and operational infrastructure.

A device that performs well in isolation but cannot demonstrate real-world impact, integrate with hospital systems, or align with evolving reimbursement models is disadvantaged, regardless of its technical merit. In this environment, translation is not downstream. It is part of the product.

This shift exposes a truth about defensibility. In healthcare, advantage is not secured by novelty alone, but by execution: the ability to embed solutions into everyday practice, support them over time, and continuously prove value in real-world settings. Incremental performance gains still matter, but less than the capacity to deliver sustained, system-level impact.
 
Life sciences and the long road to impact

Life sciences can appear insulated from translation challenges, protected by the scale, rigour, and regulatory discipline of drug development. The sector faces its own gap between discovery and impact. Clinical trials remain slow, expensive, and often poorly reflective of the patients that medicines are meant to serve. Recruitment delays extend timelines and inflate costs; limited diversity undermines generalisability and confidence in real-world effectiveness.
Even after approval, translation is far from complete. Uptake can be constrained by fragmented diagnostic pathways, limited clinician awareness, operational bottlenecks, and complex or misaligned reimbursement structures. A therapy can be scientifically sound and regulator-approved yet struggle to reach the patients who would benefit most.
You might also:
 
Here, as elsewhere, innovation outpaces translation. The science advances faster than the systems designed to deliver it. The consequence is avoidable delay, inefficiency, and inequity - not because breakthroughs are lacking, but because the pathways to routine use are fragile.

Solving this does not require less innovation. It requires stronger, more scalable mechanisms for moving discovery into everyday clinical practice.
 
The cost of innovation theatre

Healthcare systems are not passive victims of the translation gap. They often sustain it. Procurement and commissioning processes are frequently fragmented, opaque, and slow. Decision-making is dispersed across committees with misaligned incentives and unclear ownership. Risk aversion, while often justified, becomes paralysing when no one is empowered to decide.

In this environment, pilots proliferate because they feel safe. They allow organisations to signal openness to innovation without committing to adoption. Over time, pilots become a holding pattern - activity without accountability, motion without progress.

The result is innovation theatre. Start-ups cycle through endless proofs-of-concept. Providers host demonstrations that never translate into decisions. Success is measured by participation rather than impact, and real-world benefit is deferred, sometimes indefinitely.

Translation demands something harder than enthusiasm. It requires leadership willing to make choices: scale what works, stop what does not, and accept measured, governed risk. Without that decisiveness, innovation remains performative - and patients see little benefit.
 
Industry’s responsibility in the translation gap

It is convenient to place responsibility for the translation gap on healthcare systems and regulators. Industry must confront its own role. Too many MedTech and digital health companies still approach healthcare as if success were primarily a function of technical differentiation, compelling demos, and persuasive selling. In doing so, they mistake interest for adoption and pilots for progress.

Too few teams invest early in understanding the lived realities of clinical work: time pressure, risk burden, workarounds, and constant trade-offs. Even fewer grapple with service delivery constraints, procurement dynamics, or the long-term economics of adoption and support. The result is predictable: products that function technically but fail operationally.

Translation cannot be delegated to a sales team once the product is “done”. It is not a messaging problem. It is a systems problem spanning regulation, workflow, incentives, liability, governance, and trust - and it cannot be solved late.

Companies that treat translation as a core strategic capability - designed in from day one - are the ones most likely to escape pilots, achieve scale, and deliver lasting impact.
 
Translation as a strategic capability

The next advantage in healthcare will not belong to those with the best technology. It will belong to those who can get technology adopted. Translation is not an execution detail. It is a strategic capability.

For investors, executives and directors, that means looking beyond novelty. Winning teams combine technical strength with regulatory fluency, clinical credibility, operational understanding and commercial discipline. They produce evidence that answers the questions buyers and operators face: will this work in pressured environments, fit existing workflows, clear budget hurdles and improve outcomes without creating new friction?

That is where many organisations still fall short. Products are too often designed around technical performance rather than institutional fit. Yet adoption depends less on what a tool can do in theory than on whether people can use it, trust it and take responsibility for it in practice.

Translation is therefore as much organisational as technological. It requires leadership willing to absorb short-term disruption in pursuit of long-term gains. Those that build for real-world constraints will scale. Those that do not will continue to confuse innovation with impact.
 
Change, not just tools

Healthcare organisations are not blank slates onto which new technologies can be dropped. They are complex systems in which any new tool alters workflows, responsibilities, risk allocation and decision-making. Adoption is therefore not a deployment exercise. It is a change-management problem.

That is where value is often lost. Training, operational support, governance and leadership attention are routinely treated as secondary to product build or launch. In practice, they determine whether a technology becomes embedded or fades after initial enthusiasm. Durable impact comes not at implementation, but through sustained use.

AI sharpens the point. The technical progress is real, but benchmark performance will not by itself determine commercial value. Tools must fit workflows, support accountability, earn clinical trust and operate within governance and liability constraints. A model can perform well in validation and still fail in practice if it adds friction or ambiguity.

For investors, executives and directors, the lesson is straightforward: healthcare value is created not by tools alone, but by organisations able to absorb and sustain change.
 
What taking translation seriously looks like

Taking translation seriously means changing what the sector rewards. That starts with a simple shift: judging innovation not only by novelty or technical performance, but by adoption readiness.

That means backing teams that can navigate regulation, fit products into workflows and show measurable impact in real settings. It means providers engaging earlier with innovators, with clearer ownership and shared accountability. It also means treating pilots as decision tools, not theatre: time-bound, outcome-driven and designed to support scale or stop choices.

The broader point is cultural as much as operational. Healthcare spends too much time celebrating novelty and too little on disciplined adoption. Translation is not the final stage of innovation. It is the part that determines whether innovation creates value.
 
A different definition of progress

Healthcare rarely advances through dramatic disruption. Progress is usually cumulative - built through integration rather than replacement, refinement rather than rupture. This is not a failure of ambition. It is the consequence of a system that prioritises safety, trust, accountability, and continuity of care. In healthcare, change that endures is change that fits.

The organisations that succeed will be those that recognise this reality and work with it, not against it. They will resist transformation narratives that promise speed at the expense of credibility. Instead, they will focus on pragmatic progress: embedding new capabilities into existing systems, reducing friction, and improving outcomes step by step.

This translation challenge is visible across every engagement. The innovations that make it through are rarely the most radical. They are the ones that respect constraints rather than dismiss them, align incentives rather than fight them, and earn trust rather than demand it. They treat translation not as friction to overcome, but as the core work of healthcare innovation itself.
 
Takeaways

Healthcare does not need more ideas, more platforms, or louder claims of disruption. It needs leaders willing to confront where innovation fails - at the point of adoption. The bottleneck is no longer discovery - it is translation, and translation is a strategic discipline: aligning incentives, designing for real workflows, producing decision-grade evidence, and leading operational change with the courage to absorb short-term friction for long-term outcomes. Until that becomes the operating system - not a late-stage add-on - breakthroughs will keep outpacing impact, and incumbents will keep defending the status quo through inertia and politics. The next era will not be defined by who invents first, but by who delivers last: those who build translation capability will shape care, markets, and outcomes; those who do not will continue to confuse activity with progress. Innovation is abundant. Impact is not. The future belongs to those who close that gap.
view in full page